胃肠道癌症的免疫疗法
Immunotherapy in gastrointestinal cancers.
作者信息
Grierson Patrick, Lim Kian-Huat, Amin Manik
机构信息
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
出版信息
J Gastrointest Oncol. 2017 Jun;8(3):474-484. doi: 10.21037/jgo.2017.05.01.
Abstract
Gastrointestinal (GI) cancers such as gastric, esophageal, pancreas, hepatobiliary, colorectal and anal cancers are a major cause of cancer related mortality worldwide. Traditional treatment options such as chemotherapy, surgery, radiation therapy, monoclonal antibodies and anti-angiogenic agents have been the backbone of treatment of GI cancers in various stages. Current cancer research is moving forward to incorporate immunotherapies in the treatment of GI cancers either as single agent or in combination with current available treatment modalities. This review summarizes the existing and ongoing immunotherapies in the treatment of GI cancers.
摘要
胃肠道（GI）癌症，如胃癌、食管癌、胰腺癌、肝胆癌、结直肠癌和肛管癌，是全球癌症相关死亡的主要原因。传统的治疗选择，如化疗、手术、放疗、单克隆抗体和抗血管生成药物，一直是各阶段胃肠道癌症治疗的支柱。目前的癌症研究正在向前发展，将免疫疗法纳入胃肠道癌症的治疗中，无论是作为单一药物还是与现有的治疗方式联合使用。这篇综述总结了目前和正在进行的用于治疗胃肠道癌症的免疫疗法。
相似文献
1
Immunotherapy in gastrointestinal cancers.胃肠道癌症的免疫疗法
J Gastrointest Oncol. 2017 Jun;8(3):474-484. doi: 10.21037/jgo.2017.05.01.
2
The potential role of immunotherapy to treat colorectal cancer.免疫疗法在治疗结直肠癌中的潜在作用。
Expert Opin Investig Drugs. 2015 Mar;24(3):329-44. doi: 10.1517/13543784.2015.985376. Epub 2014 Dec 17.
3
Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.非结直肠癌胃肠道恶性肿瘤的免疫治疗现状
Clinics (Sao Paulo). 2018 Oct 18;73(suppl 1):e510s. doi: 10.6061/clinics/2018/e510s.
4
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.靶向PD-1通路：胃肠道癌症的新希望。
Curr Med Res Opin. 2017 Apr;33(4):749-759. doi: 10.1080/03007995.2017.1279132. Epub 2017 Jan 31.
5
Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.胃肠道癌症中的检查点抑制剂：期望与现实
World J Gastroenterol. 2017 May 7;23(17):3017-3021. doi: 10.3748/wjg.v23.i17.3017.
6
Developments in immunotherapy for gastrointestinal cancer.胃肠道癌免疫治疗的进展
Minerva Chir. 2015 Aug;70(4):217-30. Epub 2015 Apr 28.
7
Immunotherapy for GI Malignancies, Ready for Prime Time?胃肠道恶性肿瘤的免疫治疗：是否已准备好迎接黄金时代？
Ann Surg Oncol. 2023 Mar;30(3):1787-1793. doi: 10.1245/s10434-022-12668-w. Epub 2022 Oct 22.
8
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.胃肠道和肝胆癌中当前及新兴的抗血管生成疗法
Front Oncol. 2022 Oct 10;12:1021772. doi: 10.3389/fonc.2022.1021772. eCollection 2022.
9
Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy.在免疫治疗时代利用远隔效应治疗胃肠道恶性肿瘤。
J Gastrointest Oncol. 2023 Jun 30;14(3):1613-1625. doi: 10.21037/jgo-23-105. Epub 2023 Jun 2.
10
Identification of genomic features associated with immunotherapy response in gastrointestinal cancers.胃肠道癌症中与免疫治疗反应相关的基因组特征的鉴定。
World J Gastrointest Oncol. 2019 Apr 15;11(4):270-280. doi: 10.4251/wjgo.v11.i4.270.
引用本文的文献
1
Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases.结直肠癌肝转移精准手术面临的挑战与机遇
Cancers (Basel). 2024 Jun 28;16(13):2379. doi: 10.3390/cancers16132379.
2
Visualization analysis of research hotspots and trends on gastrointestinal tumor organoids.胃肠道肿瘤类器官研究热点与趋势的可视化分析
World J Gastrointest Oncol. 2024 Jun 15;16(6):2826-2841. doi: 10.4251/wjgo.v16.i6.2826.
3
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.重新定义结直肠癌之战：新兴免疫疗法及其临床疗效的全面综述。
Front Immunol. 2024 Mar 12;15:1350208. doi: 10.3389/fimmu.2024.1350208. eCollection 2024.
4
Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗食管癌患者的体成分与临床结局。
Ann Surg Oncol. 2024 Jun;31(6):3839-3849. doi: 10.1245/s10434-024-15093-3. Epub 2024 Feb 29.
5
LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies.长链非编码RNA-MUF：一种新型致癌明星分子，有望成为胃肠道恶性肿瘤的生物标志物和治疗靶点。
J Cancer. 2024 Jan 21;15(6):1498-1510. doi: 10.7150/jca.91984. eCollection 2024.
6
C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer.肿瘤相关巨噬细胞上 C 型凝集素受体 Dectin-1 的阻断可提高胃癌中抗 PD-1 的疗效。
Br J Cancer. 2023 Sep;129(4):721-732. doi: 10.1038/s41416-023-02336-5. Epub 2023 Jul 8.
7
Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.未来展望：基于人 V -set 免疫调节受体的新型免疫疗法用于消化系统肿瘤。
Int J Mol Sci. 2023 Jun 9;24(12):9945. doi: 10.3390/ijms24129945.
8
Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer.肿瘤内具核梭杆菌与食管癌的免疫反应。
Br J Cancer. 2023 Apr;128(6):1155-1165. doi: 10.1038/s41416-022-02112-x. Epub 2023 Jan 4.
9
Tumor buster - where will the CAR-T cell therapy 'missile' go?肿瘤克星——CAR-T 细胞疗法的“导弹”将飞向何方？
Mol Cancer. 2022 Oct 19;21(1):201. doi: 10.1186/s12943-022-01669-8.
10
Coating bacteria for anti-tumor therapy.用于抗肿瘤治疗的细菌包被
Front Bioeng Biotechnol. 2022 Sep 15;10:1020020. doi: 10.3389/fbioe.2022.1020020. eCollection 2022.
本文引用的文献
1
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.针对癌症中突变型KRAS的T细胞转移疗法。
N Engl J Med. 2016 Dec 8;375(23):2255-2262. doi: 10.1056/NEJMoa1609279.
2
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.错配修复缺陷与免疫检查点阻断反应
Oncologist. 2016 Oct;21(10):1200-1211. doi: 10.1634/theoncologist.2016-0046. Epub 2016 Jul 13.
3
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.靶向粘着斑激酶可使胰腺癌对检查点免疫疗法产生反应。
Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.
4
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.帕博利珠单抗治疗 PD-L1 阳性晚期胃癌患者（KEYNOTE-012）：一项多中心、开放标签、Ib 期临床试验。
Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.
5
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.在临界可切除和局部晚期胰腺癌患者中，使用CCR2抑制剂联合FOLFIRINOX靶向肿瘤相关巨噬细胞：一项单中心、开放标签、剂量探索、非随机的1b期试验。
Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.
6
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.结直肠癌综合分析显示免疫评分是比微卫星不稳定性更强的患者生存预测指标。
Immunity. 2016 Mar 15;44(3):698-711. doi: 10.1016/j.immuni.2016.02.025.
7
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
8
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.共生双歧杆菌可促进抗肿瘤免疫并增强抗程序性死亡受体配体1（PD-L1）的疗效。
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.
9
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.分子途径：靶向吲哚胺2,3-双加氧酶1及其他色氨酸双加氧酶用于癌症免疫治疗
Clin Cancer Res. 2015 Dec 15;21(24):5427-33. doi: 10.1158/1078-0432.CCR-15-0420. Epub 2015 Oct 30.
10
Developments in cancer vaccines for hepatocellular carcinoma.肝细胞癌癌症疫苗的进展
Cancer Immunol Immunother. 2016 Jan;65(1):93-9. doi: 10.1007/s00262-015-1728-y. Epub 2015 Jun 21.
Zotero 插件